LYON, France , May 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2013 results announcement, which will take place on Thursday, May 16, 2013 , before the opening of the market.
Four scientific sessions highlighting HIFU outcomes for treatment of prostate cancer One AUA accepted poster presentation highlighting Sonolith lithotripter and its exclusive ultrasound Visio Track ® localization system EDAP attending the FDA Public Workshop on prostate cancer clinical trial design
First quarter total revenue of approximately EUR 5.9 million ( USD 7.8 million ), up 23% year-over-year Ten lithotripsy devices sold in first quarter 2013 Received FDA acceptance for PMA filing on March 26, 2013 , for Ablatherm®-HIFU for treatment of low risk, localized prostate cancer LYON, France
Highlights Record fourth quarter 2012 revenue of EUR 9.5 million ( USD 12.3 million ), up 25.3% year-over-year Record full year revenue of EUR 26.1 million ( USD 33.6 million ), up 16.9% year-over-year Record lithotripsy sales in 2012 PMA for Ablatherm®-HIFU for treatment of low risk, localized
LYON, France , March 12, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its fourth quarter and full year 2012 results announcement, which will take place on Tuesday, April 2, 2013 , before the opening of the